ATE500752T1 - Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom - Google Patents

Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom

Info

Publication number
ATE500752T1
ATE500752T1 AT05722048T AT05722048T ATE500752T1 AT E500752 T1 ATE500752 T1 AT E500752T1 AT 05722048 T AT05722048 T AT 05722048T AT 05722048 T AT05722048 T AT 05722048T AT E500752 T1 ATE500752 T1 AT E500752T1
Authority
AT
Austria
Prior art keywords
treatment
insulin resistance
sphingolipids
prevention
type
Prior art date
Application number
AT05722048T
Other languages
English (en)
Inventor
Willem Nieuwenhuizen
Aloysius Havekes
Josephus Emeis
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34975255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE500752(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP04075848A external-priority patent/EP1576894A1/de
Application filed by Tno filed Critical Tno
Application granted granted Critical
Publication of ATE500752T1 publication Critical patent/ATE500752T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05722048T 2004-03-16 2005-03-15 Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom ATE500752T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04075848A EP1576894A1 (de) 2004-03-16 2004-03-16 Verwendung von Sphingolipiden zur Behandlung und Prävention von TYP 2 DIABETES, Insulinresistenz und METABOLISCHEN SYNDROMS
EP04077088 2004-07-19
PCT/NL2005/000193 WO2005087023A1 (en) 2004-03-16 2005-03-15 The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome

Publications (1)

Publication Number Publication Date
ATE500752T1 true ATE500752T1 (de) 2011-03-15

Family

ID=34975255

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05722048T ATE500752T1 (de) 2004-03-16 2005-03-15 Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom

Country Status (7)

Country Link
US (3) US20070207983A1 (de)
EP (1) EP1729597B1 (de)
JP (1) JP5154218B2 (de)
AT (1) ATE500752T1 (de)
AU (1) AU2005220692A1 (de)
DE (1) DE602005026785D1 (de)
WO (1) WO2005087023A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
BRPI0517701A8 (pt) * 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
US20090117198A1 (en) 2006-05-31 2009-05-07 Hiroshi Kawakami Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level
EP2594565B1 (de) 2007-05-31 2018-10-24 Genzyme Corporation Glukosylceramid-Synthase-Hemmer vom 2-Acylaminpropanol-Typ
KR101640263B1 (ko) 2007-10-05 2016-07-15 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
JP2011529500A (ja) 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
CN102271678B (zh) 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
CA2739787A1 (en) * 2008-10-08 2010-04-15 Nucitec S.A. De C.V. .beta.-hydroxy-.gamma.-aminophosphonates and methods for the preparation and use thereof
WO2010131718A1 (ja) * 2009-05-13 2010-11-18 丸大食品株式会社 鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤
JP6169978B2 (ja) * 2012-01-25 2017-07-26 株式会社Ｊ−オイルミルズ スフィンゴイド塩基を含む抽出物の製造方法
US9492466B2 (en) 2012-06-14 2016-11-15 Nucitec S.A. De C.V. Beta-hydroxy-gamma-aminophosphonates for treating immune disorders
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
CA3158256A1 (en) * 2019-11-13 2021-05-20 Aimee EDINGER Drug formulations and methods of treatment for metabolic disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
IT1235162B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisosfingolipidi
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
JP3157531B2 (ja) * 1991-03-08 2001-04-16 昭和産業株式会社 血中コレステロール低下剤
US5232837A (en) * 1991-08-05 1993-08-03 Emory University Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
US6190894B1 (en) * 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
US5478860A (en) * 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US20020182250A1 (en) * 1995-09-06 2002-12-05 Goro Hori Lipid metabolism improving agent
EP0888458A4 (de) * 1996-02-20 2004-05-06 Sloan Kettering Institutefor C Kombination von pkc-inhibitoren und therapeutischen agenzien zur behandlung von krebs
EP1520583B1 (de) * 1997-04-10 2009-01-28 Kyowa Hakko Kirin Co., Ltd. NKT-Zellenaktivatoren, die Alpha-Glycosylceramide enthalten
US6800661B1 (en) * 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
CA2316041A1 (en) * 1997-12-30 1999-07-08 Pam Fredman Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
EP1053243B1 (de) * 1998-02-12 2011-03-30 Emory University Sphingolipid-derivate und verfahren zu deren verwendung
CA2362549A1 (en) * 1999-02-24 2000-08-31 John Hopkins University Compositions and methods for modulating serum cholesterol
EP1195165A4 (de) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co Fibrose inhibitore die als aktiven bestandteil sphingosin-a-phosphat oder dessen rezeptoragonisten enthalten
JP2001213858A (ja) * 1999-11-24 2001-08-07 Sagami Chem Res Center スフィンゴシン誘導体
JP2003523336A (ja) * 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
AU2001255199A1 (en) * 2000-03-28 2001-10-08 The Liposome Company, Inc. Ceramide derivatives and method of use
US6949247B2 (en) * 2000-12-28 2005-09-27 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Stable skin care compositions containing a retinoid and a retinoid booster system
JP2002226394A (ja) * 2001-02-01 2002-08-14 Meiji Milk Prod Co Ltd 脂質代謝改善組成物
JP4958339B2 (ja) * 2001-03-21 2012-06-20 雪印メグミルク株式会社 脂質代謝改善剤
US20040241249A1 (en) * 2001-06-18 2004-12-02 Tina Sampalis Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
JP4568464B2 (ja) * 2001-11-07 2010-10-27 雪印乳業株式会社 記憶障害予防治療剤
MXPA04011312A (es) * 2002-05-17 2005-02-14 Esperion Therapeutics Inc Metodo para el tratamiento de desordenes dislipidemicos.
DE602004020316D1 (de) * 2003-01-20 2009-05-14 Tno Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.
JP4585172B2 (ja) * 2003-01-31 2010-11-24 森永乳業株式会社 骨形成促進剤
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
JP4341891B2 (ja) * 2003-03-05 2009-10-14 森永乳業株式会社 血糖降下組成物
WO2004078168A1 (en) * 2003-03-07 2004-09-16 Korea Atomic Energy Research Institute A composition comprising phytosphingosine or a derivative thereof

Also Published As

Publication number Publication date
DE602005026785D1 (de) 2011-04-21
US20070207983A1 (en) 2007-09-06
JP2007529507A (ja) 2007-10-25
JP5154218B2 (ja) 2013-02-27
EP1729597B1 (de) 2011-03-09
US20110003772A1 (en) 2011-01-06
WO2005087023A1 (en) 2005-09-22
AU2005220692A1 (en) 2005-09-22
EP1729597A1 (de) 2006-12-13
US20090203651A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
DE602005026785D1 (de) Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom
TW200602043A (en) Use of indazolecarboxamide derivatives for preparing a medicinal product intended for the treatment and prevention of malaria
MY148566A (en) Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
TW200730540A (en) Novel peptide compounds
TW200744659A (en) Preparation for preventing and ameliorating wrinkle
RU2010143817A (ru) Лекарственное средство, включающее совместное применение или комбинацию ингибитора dpp-iv и другого лекарственного средства для лечения диабета
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
MY142807A (en) Benzimidazole derivative and use thereof.
DE502004002556D1 (de) Tripeptide und deren derivate für die kosmetische verwendung zur verbesserung der hautstruktur
MY145460A (en) Biaryl ether urea compounds
BR0317703A (pt) Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
MX2009003073A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk.
MY151295A (en) Pyrimidyl indoline compound
MX2011008839A (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de transportador de glucosa dependiente de sodio 1.
MY151072A (en) Heteroaryl derivative
DE602004030004D1 (de) Verbindungen zur behandlung von stoffwechselstörungen
GEP20104882B (en) Age inhibitors
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
TW200744589A (en) Pharmaceutical composition
AR044175A1 (es) Compuestos de cefemo
EP2055188A4 (de) Polyphenolgehaltsteigerndes mittel für pflanze

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties